Skip to main content

Switching Biologics in JIA

While there are numerous agents approved for use in juvenile idiopathic arthritis, little is know about actual use biological disease-modifying antirheumatic drug (DMARD) use or switching in the biologic era.  A cohort comparison study has shown that after an unsuccessful trial of a first biologic, changing to a second TNFi is as effective as switching to a non-TNFi biologic.

The study included polyarticular JIA patients in two UK cohorts: the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study [BSPAR-ETN] and the Biologics for Children with Rheumatic Diseases [BCRD]. 

From a total of 2361 patients enrolled, 1152 patients started their first biologic (91% on a TNFi).

Nearly 23% (270) were changed to a second biologic, and 5% (61) went on to a third biologic.

Of the 240 patients failing a first biologic, 194 (81%) started a second TNFi and 46 (19%) started a non-TNFi.

The outcomes showed no difference between those starting a second TNFi vs non-TNFi biologic  with no statistical edge according to the ACR Pedi 90 response (adjusted odds ratio [OR] 2·5, 95% CI 0·8–7·9; p=0·11) or minimal disease activity (adjusted OR 1·6, 95% CI 0·6–3·8; p=0·33).

They found no evidence that switching to a second non-TNFi biologic was more beneficial than a second TNFi (nor was it inferior).

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject